Kahn Brothers Group Inc. DE decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 799,465 shares of the medical equipment provider’s stock after selling 118,934 shares during the period. Hologic accounts for about 5.5% of Kahn Brothers Group Inc. DE’s holdings, making the stock its 8th largest position. Kahn Brothers Group Inc. DE owned approximately 0.29% of Hologic worth $36,280,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Oregon Public Employees Retirement Fund raised its position in shares of Hologic by 15.2% in the first quarter. Oregon Public Employees Retirement Fund now owns 29,166 shares of the medical equipment provider’s stock valued at $1,241,000 after buying an additional 3,843 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD raised its position in shares of Hologic by 10.6% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 21,345 shares of the medical equipment provider’s stock valued at $908,000 after buying an additional 2,049 shares during the last quarter. KAMES CAPITAL plc acquired a new position in shares of Hologic during the first quarter valued at about $718,000. Russell Investments Group Ltd. raised its position in shares of Hologic by 10.4% in the first quarter. Russell Investments Group Ltd. now owns 321,371 shares of the medical equipment provider’s stock valued at $13,678,000 after buying an additional 30,190 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D raised its position in shares of Hologic by 165.0% in the first quarter. State of New Jersey Common Pension Fund D now owns 321,200 shares of the medical equipment provider’s stock valued at $13,667,000 after buying an additional 200,000 shares during the last quarter. 94.43% of the stock is currently owned by institutional investors.

Hologic, Inc. (NASDAQ:HOLX) traded up 0.99% during midday trading on Friday, hitting $37.91. 2,976,625 shares of the stock traded hands. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80. The stock has a market cap of $10.63 billion, a price-to-earnings ratio of 14.12 and a beta of 0.90. The company has a 50-day moving average price of $41.66 and a 200 day moving average price of $42.74.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.51 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Kahn Brothers Group Inc. DE Lowers Position in Hologic, Inc. (HOLX)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2017/08/27/kahn-brothers-group-inc-de-lowers-position-in-hologic-inc-holx.html.

Several brokerages recently issued reports on HOLX. Stifel Nicolaus lifted their price objective on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, May 11th. Jefferies Group LLC reissued a “buy” rating and set a $49.00 price objective on shares of Hologic in a report on Wednesday, June 28th. Bank of America Corporation reissued a “neutral” rating and set a $48.00 price objective (up from $44.00) on shares of Hologic in a report on Friday, July 21st. Canaccord Genuity reissued a “buy” rating and set a $53.00 price objective on shares of Hologic in a report on Tuesday, May 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $51.00 price objective on shares of Hologic in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $48.64.

In related news, insider Peter J. Valenti III sold 10,005 shares of Hologic stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $43.44, for a total value of $434,617.20. Following the completion of the sale, the insider now owns 20,994 shares in the company, valued at $911,979.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Elaine Ullian sold 8,938 shares of Hologic stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $43.99, for a total transaction of $393,182.62. Following the completion of the sale, the director now owns 23,810 shares of the company’s stock, valued at approximately $1,047,401.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,358 shares of company stock valued at $1,849,803. Insiders own 0.79% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.